Ribavirin (Virazole)

Subscribe to Selected New Research on Ribavirin

3214 relevant articles (545 outcomes, 572 trials/studies) found for this Drug

Description: A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.

Also Known As:

Virazole; Ribasphere; Dermatech Brand of Ribavirin; Essex Brand of Ribavirin; Grossman Brand of Ribavirin; ICN Brand of Ribavirin; ICN-1229; Pharmacia Brand of Ribavirin; Rebetol; Ribamide; Ribamidil; Ribamidyl; Schering-Plough Brand of Ribavirin; Three Rivers Pharmaceuticals Brand of Ribavirin; Vilona; Viramide; Virazide; ICN 1229; ICN1229; Schering Plough Brand of Ribavirin; Ribovirin; Tribavirin; 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-

Relationship Network

Drug Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1

ribavirin amidine: 15

Rebetron: 5

1-(5'-O-sulfamoyl-beta-ribofuranosyl)(1,2,4)triazole-3-thiocarboxamide: 4

methyl 1-ribofuranosyl-1,2,4-triazole-3-carboxamidate: 2

ribavirin 2',3',5'-triacetate: 2

ribavirin 5'-sulfamate: 1

taribavirin: 1

tributylribavirin: 1

1-(4-thio-beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide

1-(5'-O-sulfamoyl-beta-D-ribofuranosyl)(1,2,4)triazole-3-carbonitrile

2',3'-didehydro-2',3'-dideoxytiazofurin

2',3'-dideoxytiazofurin

2-(3-amino-3-deoxyxylofuranosyl)thiazole-4-carboxamide

2-ribofuranosyl-1,2,3-triazole-4,5-dicarboxamide

3-ribofuranosyl-1,2,4-triazole-5-carboxamide

4-fluoro-1-ribofuranosyl-1H-pyrazole-3-carboxamide

5'-nor carbocyclic ribavirin

5'-O-galactopyranosyl ribavirin

5'-O-glucopyranosyl ribavirin

adenylyl-(3'-5')-virazole

ethyl 1-ribofuranosyl-1,2,4-triazole-3-carboximidate

ribavirin 5'-diphosphate

tiazofurin monophosphate

Experts

1.	Zeuzem, Stefan: 16 articles (08/2008 - 06/2003)
2.	Yu, Ming-Lung: 12 articles (09/2008 - 10/2004)
3.	Dai, Chia-Yen: 12 articles (09/2008 - 10/2004)
4.	Kumada, Hiromitsu: 12 articles (01/2008 - 04/2003)
5.	Soriano, Vincent: 12 articles (01/2008 - 05/2003)
6.	Marcellin, Patrick: 12 articles (10/2007 - 04/2002)
7.	Chuang, Wan-Long: 11 articles (09/2008 - 10/2004)
8.	Ferenci, Peter: 11 articles (08/2008 - 11/2002)
9.	Fried, Michael W: 10 articles (10/2008 - 09/2002)
10.	Chang, Wen-Yu: 10 articles (04/2007 - 10/2004)

Related Diseases

1.	Chronic Hepatitis C 10/01/2006 - "INTERPRETATION AND CONCLUSIONS: These results show that combination therapy with Peg-IFNalpha2b plus ribavirin is highly efficacious in hemophiliacs with chronic hepatitis C." 01/01/2002 - "Combination therapy with subcutaneous interferon-alpha-2b [3 million units (MU) three times per week] plus oral ribavirin (1000 to 1200 mg/day) has proven effective in several well designed trials of 24 to 48 weeks' duration in adult patients with compensated chronic hepatitis C" 01/01/2003 - "In conclusion, combination therapy comprising subcutaneous peginterferon-alpha-2a (40kD) and oral ribavirin is an important new treatment option for chronic hepatitis C" 01/01/2008 - "In pegylated IFN-alfa/ribavirin therapy for chronic hepatitis C, improved DC function is related with successful HCV eradication" 07/01/2007 - "BACKGROUND/AIM: An understanding of ribavirin's beneficial effects on treatment outcome in chronic hepatitis C (CH-C) may help to develop new treatment approaches" Order ALL the reference details at left...
2.	Infection 03/01/2008 - "CONCLUSIONS: This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR." 01/01/2004 - "The most effective treatment for chronic HCV infection is combination antiviral therapy with peginterferon and ribavirin" 02/01/1993 - "The nucleoside analog--ribavirin--was highly effective against Caraparu virus in repeated treatment schedules begun on either day -1, day 0, or day +1 of infection" 09/01/2008 - "Current standard treatment with a combination of IFN-alpha and ribavirin has improved the prognosis for many HCV sufferers; however, infection is very difficult to treat successfully and the protocol for treatment is neither simple, well tolerated nor economically favorable" 07/21/1998 - "NIH351 was 50- to 90-fold more potent against RSV strain A2 than was ribavirin, the presently approved drug for clinical management of RSV infection" Order ALL the reference details at left...
3.	Hepatitis C 11/01/2002 - "Thus, the combination of peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment." 01/01/2002 - "The substituted IFN had an enhanced pharmacokinetic profile in both animal and human studies, and, when combined with ribavirin, was very effective in reducing hepatitis C viral load and maintaining sustained viral suppression in patients." 05/01/2005 - "Nonetheless, there are now data to support the safety, tolerability and efficacy of hepatitis C treatment with peginterferon plus ribavirin in HIV-infected patients, and the impetus to treat these patients is, therefore, strong" 10/01/2008 - "Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin." 02/01/2006 - "METHODS: We initiated an open-label pilot study to investigate the efficacy of CIFN plus ribavirin on viral kinetics, sustained virological response (SVR), and histological response in hepatitis C non-responder patients" Order ALL the reference details at left...
4.	Fibrosis (Cirrhosis) 12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis." 01/01/2008 - "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis." 04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed" 03/01/2005 - "A recent clinical trial of peginterferon alpha-2a plus ribavirin in African American patients resulted in a higher SVR rate, 26%, than observed previously, and 90% of patients showed stabilization or improvement in fibrosis" 01/01/2008 - "CONCLUSIONS: PEG-IFN-alpha2b plus ribavirin for 48 weeks is an efficacious and well-tolerated treatment regimen for patients with HCV-induced cirrhosis" Order ALL the reference details at left...
5.	Human Influenza (Influenza) 01/01/1999 - "Ribavirin is an antiviral given by small particle aerosol that is approved for the treatment of respiratory syncytial virus disease; it is also effective for the treatment of influenza" 01/01/1992 - "Thus, we attempted to determine the length of time of ribavirin aerosol necessary for effective treatment of influenza and RSV" 11/01/1986 - "Ribavirin, recently licensed for treatment of respiratory syncytial virus disease, is also effective for treatment of both influenza A and B viruses." 03/17/1997 - "Aerosol and intravenous ribavirin has been used to treat severe influenza in small numbers of immunosuppressed patients, but the efficacy of ribavirin by either route has not been established in such patients" 03/01/1992 - "Aerosolized ribavirin has also shown promise in treatment of patients who are severely ill with influenza A and B." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Interferons
2.	Interferon-alpha (Interferon Alfa)
3.	Amantadine (Aman)
4.	Interferon Alfa-2b (Interferon Alfa 2b)
5.	RNA (Ribonucleic Acid)
6.	peginterferon alfa-2b (Pegintron)
7.	Carbon Monoxide
8.	peginterferon alfa-2a (Pegasys)
9.	Antiviral Agents (Antivirals)
10.	Alanine Transaminase (SGPT)

Related Therapies and Procedures

1.	Liver Transplantation
2.	Retreatment
3.	Transplantation (Transplant Recipients)
4.	Aftercare (After-Treatment)
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Chronic Hepatitis C

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 646 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>